| Title: |
Comparison of 2‐year clinical outcomes with sirolimus and paclitaxel‐eluting stents for patients with diabetes: Results of the Registro Regionale AngiopLastiche Emilia‐Romagna Registry |
| Authors: |
Balducelli, Marco; Ortolani, Paolo; Marzaroli, Paolo; Piovaccari, Giancarlo; Menozzi, Alberto; Manari, Antonio; Sangiorgio, Pietro; Tarantino, Fabio; Rossi, Rosario; Maresta, Aleardo; Tondi, Stefano; Passerini, Francesco; Guastaroba, Paolo; Grilli, Roberto; Marzocchi, Antonio |
| Source: |
Catheterization and Cardiovascular Interventions ; volume 75, issue 3, page 327-334 ; ISSN 1522-1946 1522-726X |
| Publisher Information: |
Wiley |
| Publication Year: |
2009 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Background: Long‐term outcomes of percutaneous coronary interventions (PCI) with sirolimus‐eluting stents (SES) compared to paclitaxel‐eluting‐stents (PES) in unselected diabetics in routine practice is still debated. Objective: This study compared the 2‐year incidence of MACE (all‐cause mortality, nonfatal myocardial infarction and target vessel revascularization) of SES and PES in a real‐world setting of patients with diabetes. Design: Observational, multicenter, nonrandomized study. Setting: Prospective web‐based registry (REAL Registry; study period, 2002–2005) comprising all 13 hospitals performing PCI. Patients: Among the 945 eligible patients treated with either SES alone ( n = 606) or PES alone ( n = 339), 29% were insulin‐requiring, 72% had multivessel coronary disease, 26% had prior myocardial infarction and 10% had poor left ventricular function. Measurements: Unadjusted and propensity score‐adjusted 2‐year clinical outcome. Results: After propensity score adjustment, 2‐year MACE incidence in the SES and PES groups was equivalent (23.3% vs. 23.7%, HR 1.01, 95%CI 0.72–1.42, P = 0.96). Adjusted 2‐year angiographic stent thrombosis occurred in 1.1% of the SES patients versus 2.6% of the PES patients ( P = 0.15). In this large, real‐world, diabetic population treated with DES, there was no difference in outcome between SES and PES. Further studies are needed to demonstrate the long‐term safety of different types of DES in patients with diabetes. © 2009 Wiley‐Liss, Inc. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1002/ccd.22293 |
| Availability: |
https://doi.org/10.1002/ccd.22293; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fccd.22293; https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.22293 |
| Rights: |
http://onlinelibrary.wiley.com/termsAndConditions#vor |
| Accession Number: |
edsbas.DEABD92 |
| Database: |
BASE |